Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
| ▸ | HRH1 | P35367 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604289 | 0.90 | SLC6A2 (0.55) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL7810676 | 0.86 | HDAC8 (0.55) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL14698741 | 0.82 | HDAC8 (0.74) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL14707050 | 0.78 | HDAC8 (0.70) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL11384662 | 0.77 | SLC6A2 (0.76) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL29460460 | 0.77 | SLC6A2 (0.76) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL29485933 | 0.77 | SLC6A2 (0.76) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL15559678 | 0.77 | HDAC8 (0.64) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL29485969 | 0.77 | HDAC8 (0.69) | HDAC8HDAC6HDAC1HDAC2CYP3A4 | |
| SCHEMBL27089595 | 0.77 | HDAC8 (0.69) | HDAC8HDAC6HDAC1HDAC2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| EP-0820443-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING DIABETES | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0820443-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | claimed |
| WO-1996031481-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| EP-0820443-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING DIABETES | NOVO NORDISK AS (DK) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| EP-0820443-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031481-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | HDAC8 1128/4885HDAC6 143/4885HDAC1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.